
## Leslie M Randall

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8995703/publications.pdf Version: 2024-02-01



LESUE M RANDALL

#	Article	IF	CITATIONS
1	Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. Journal of Clinical Oncology, 2019, 37, 2317-2328.	1.6	289
2	High-volume ovarian cancer care: Survival impact and disparities in access for advanced-stage disease. Gynecologic Oncology, 2014, 132, 403-410.	1.4	141
3	Bevacizumab toxicities and their management in ovarian cancer. Gynecologic Oncology, 2010, 117, 497-504.	1.4	91
4	Multi-disciplinary summit on genetics services for women with gynecologic cancers: A Society of Gynecologic Oncology White Paper. Gynecologic Oncology, 2017, 146, 217-224.	1.4	89
5	A phase II, multicenter, open-label trial of OTL38 injection for the intra-operative imaging of folate receptor-alpha positive ovarian cancer. Gynecologic Oncology, 2019, 155, 63-68.	1.4	83
6	Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study. Gynecologic Oncology, 2009, 112, 583-589.	1.4	71
7	Inhibition of Enhancer of Zeste Homolog 2 (EZH2) Expression Is Associated With Decreased Tumor Cell Proliferation, Migration, and Invasion in Endometrial Cancer Cell Lines. International Journal of Gynecological Cancer, 2013, 23, 997-1005.	2.5	60
8	Socioeconomic status as a predictor of adherence to treatment guidelines for early-stage ovarian cancer. Gynecologic Oncology, 2015, 138, 121-127.	1.4	49
9	The genetic prediction of risk for gynecologic cancers. Gynecologic Oncology, 2016, 141, 10-16.	1.4	41
10	Bevacizumab in the treatment of ovarian cancer. Biologics: Targets and Therapy, 2011, 5, 1.	3.2	30
11	lt's time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer. Gynecologic Oncology, 2018, 151, 555-561.	1.4	29
12	Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Gynecologic Oncology, 2020, 156, 423-429.	1.4	23
13	Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study. International Journal of Gynecological Cancer, 2016, 26, 125-132.	2.5	22
14	Uterine leiomyomatosis with intracaval and intracardiac extension. Gynecologic Oncology Case Reports, 2012, 2, 130-132.	0.9	18
15	Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial. Gynecologic Oncology, 2012, 124, 563-568.	1.4	17
16	A profile on the FoundationFocus CDxBRCA tests. Expert Review of Molecular Diagnostics, 2020, 20, 285-292.	3.1	15
17	Germline and Somatic Tumor Testing in Gynecologic Cancer Care. Obstetrics and Gynecology Clinics of North America, 2019, 46, 37-53.	1.9	8
18	Prospective evaluation of an in vitro radiation resistance assay in locally advanced cancer of the uterine cervix: A Southwest Oncology Group Study. Gynecologic Oncology, 2010, 119, 417-421.	1.4	7

Leslie M Randall

#	Article	IF	CITATIONS
19	Clinical commentary: Medical ethics and the ramifications of equipoise in clinical research. Is a confirmatory trial using a non-bevacizumab containing arm feasible in patients with recurrent cervical cancer?. Gynecologic Oncology, 2014, 134, 447-449.	1.4	6
20	Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study. Gynecologic Oncology, 2020, 159, 79-87.	1.4	6
21	Rapid progression of disease in two cases of undifferentiated endometrial carcinoma. Gynecologic Oncology Reports, 2019, 27, 65-68.	0.6	5
22	Role and clinical application of next-generation sequencing (NGS) for ovarian cancer. Journal of Gynecologic Oncology, 2017, 28, e51.	2.2	3
23	The American Society of Clinical Oncology 50th Annual Meeting 2014: An overview and summary of selected abstracts. Gynecologic Oncology, 2014, 134, 222-227.	1.4	2
24	Incidence Rates of Gynecologic Cancers in the U.S. Active Duty Military Population. Military Medicine, 2020, 185, e1590-e1595.	0.8	2
25	Ovarian Cancer Maintenance: Practiceâ€Changing Data Calls for Changing Practice. Oncologist, 2019, 24, 576-579.	3.7	0